<DOC>
	<DOC>NCT02290041</DOC>
	<brief_summary>Clinical trial phase I/II, of test of concept, blind double, and controlled with placebo, randomized 2:1 (Treatment: placebo), in which a total of 15 patients will be included</brief_summary>
	<brief_title>Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response</brief_title>
	<detailed_description>Clinical trial phase I/II, of test of concept, blind double, controlled with placebo, randomized, in which a total of 15 patients will be included In an initial phase, there will be included 5 patients of sequential form, with a minimum of 15 days of safety period between the first infusion of a patient and the first one of the following patient. These first 5 patients will not be randomized, being all of them treated with the medicine in investigation. When the last one of these 5 patients has received the first three foreseen doses, the safety information will be evaluated by an Independent Data Monitoring Committee. If this evaluation is positive, it will be continued by the trial being recruited the rest of patients (n = 10). After randomization, 5 of these patients will receive cellular therapy and the other 5 will receive an infusion of the placebo product.</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<criteria>Age&gt; 18 years. Both sexes In antiretroviral therapy for HIV Infection HIV Viral load &lt;50 copies / ml during &gt;1 year Value of CD4 + &lt;350/mcl Immunological discordant response defined as an increase &lt;75 or &lt;150 in CD4+ cell counts after one or two years of undetectable viraemia, respectively, with regard to the basal determination or as an recount of CD4 + &lt;350/mcl after 3 years of antiretroviral treatment and undetectable viraemia (&lt;50 copies/ml) â‰¥ 1 year Writing informed consent Commitment of utilization of a contraceptive method of proved efficiency in both men and women during the duration of the clinical trial Pregnancy, lactation, or denial to the use of contraceptive methods of proved efficiency in both men and women Opportunistic infections with ongoing treatment Hepatitis B virus/hepatitis C virus coinfection Hepatic cirrhosis stadium C of Child Pugh's classification of any a aetiology Portal hypertension and / or hypersplenism of any aetiology Presence malignant neoplasia Treatment with steroids, immunomodulator, interferon, chemotherapy or any medicinal product that could reverberate in the number of CD4 in the last twelve months Any analytical alteration 3 or 4 grade (AIDS Clinical Trials Group scale), confirmed, in the analytical prior to the first infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>mesenchymal stem cells</keyword>
	<keyword>Virus of human immunodeficiency Infection</keyword>
</DOC>